146 related articles for article (PubMed ID: 16279768)
1. SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors.
Martinez A; Alonso M; Castro A; Dorronsoro I; Gelpí JL; Luque FJ; Pérez C; Moreno FJ
J Med Chem; 2005 Nov; 48(23):7103-12. PubMed ID: 16279768
[TBL] [Abstract][Full Text] [Related]
2. Non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: study of structural requirements for thiadiazolidinone derivatives.
Castro A; Encinas A; Gil C; Bräse S; Porcal W; Pérez C; Moreno FJ; Martínez A
Bioorg Med Chem; 2008 Jan; 16(1):495-510. PubMed ID: 17919914
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory mode of N-phenyl-4-pyrazolo[1,5-b] pyridazin-3-ylpyrimidin-2-amine series derivatives against GSK-3: molecular docking and 3D-QSAR analyses.
Xiao J; Guo Z; Guo Y; Chu F; Sun P
Protein Eng Des Sel; 2006 Feb; 19(2):47-54. PubMed ID: 16339768
[TBL] [Abstract][Full Text] [Related]
4. Selectivity criterion for pyrazolo[3,4-b]pyrid[az]ine derivatives as GSK-3 inhibitors: CoMFA and molecular docking studies.
Patel DS; Bharatam PV
Eur J Med Chem; 2008 May; 43(5):949-57. PubMed ID: 17707953
[TBL] [Abstract][Full Text] [Related]
5. 3D QSAR studies on GSK-3 inhibition by aloisines.
Zeng M; Jiang Y; Zhang B; Zheng K; Zhang N; Yu Q
Bioorg Med Chem Lett; 2005 Jan; 15(2):395-9. PubMed ID: 15603961
[TBL] [Abstract][Full Text] [Related]
6. 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity.
Dessalew N; Bharatam PV
Eur J Med Chem; 2007 Jul; 42(7):1014-27. PubMed ID: 17335939
[TBL] [Abstract][Full Text] [Related]
7. Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry.
Mendgen T; Steuer C; Klein CD
J Med Chem; 2012 Jan; 55(2):743-53. PubMed ID: 22077389
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.
Polychronopoulos P; Magiatis P; Skaltsounis AL; Myrianthopoulos V; Mikros E; Tarricone A; Musacchio A; Roe SM; Pearl L; Leost M; Greengard P; Meijer L
J Med Chem; 2004 Feb; 47(4):935-46. PubMed ID: 14761195
[TBL] [Abstract][Full Text] [Related]
9. QSAR modeling of the inhibition of glycogen synthase kinase-3.
Katritzky AR; Pacureanu LM; Dobchev DA; Fara DC; Duchowicz PR; Karelson M
Bioorg Med Chem; 2006 Jul; 14(14):4987-5002. PubMed ID: 16650999
[TBL] [Abstract][Full Text] [Related]
10. Use of molecular modeling, docking, and 3D-QSAR studies for the determination of the binding mode of benzofuran-3-yl-(indol-3-yl)maleimides as GSK-3beta inhibitors.
Kim KH; Gaisina I; Gallier F; Holzle D; Blond SY; Mesecar A; Kozikowski AP
J Mol Model; 2009 Dec; 15(12):1463-79. PubMed ID: 19440740
[TBL] [Abstract][Full Text] [Related]
11. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
12. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.
Martinez A; Alonso M; Castro A; Pérez C; Moreno FJ
J Med Chem; 2002 Mar; 45(6):1292-9. PubMed ID: 11881998
[TBL] [Abstract][Full Text] [Related]
13. N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy.
Tavares FX; Boucheron JA; Dickerson SH; Griffin RJ; Preugschat F; Thomson SA; Wang TY; Zhou HQ
J Med Chem; 2004 Sep; 47(19):4716-30. PubMed ID: 15341487
[TBL] [Abstract][Full Text] [Related]
14. 4-Acylamino-6-arylfuro[2,3-d]pyrimidines: potent and selective glycogen synthase kinase-3 inhibitors.
Maeda Y; Nakano M; Sato H; Miyazaki Y; Schweiker SL; Smith JL; Truesdale AT
Bioorg Med Chem Lett; 2004 Aug; 14(15):3907-11. PubMed ID: 15225695
[TBL] [Abstract][Full Text] [Related]
15. Glycogen synthase kinase-3 inhibition by 3-anilino-4-phenylmaleimides: insights from 3D-QSAR and docking.
Prasanna S; Daga PR; Xie A; Doerksen RJ
J Comput Aided Mol Des; 2009 Feb; 23(2):113-27. PubMed ID: 18839067
[TBL] [Abstract][Full Text] [Related]
16. Probing the physicochemical and structural requirements for glycogen synthase kinase-3alpha inhibition: 2D-QSAR for 3-anilino-4-phenylmaleimides.
Sivaprakasam P; Xie A; Doerksen RJ
Bioorg Med Chem; 2006 Dec; 14(24):8210-8. PubMed ID: 17010615
[TBL] [Abstract][Full Text] [Related]
17. 5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3.
Palomo V; Perez DI; Perez C; Morales-Garcia JA; Soteras I; Alonso-Gil S; Encinas A; Castro A; Campillo NE; Perez-Castillo A; Gil C; Martinez A
J Med Chem; 2012 Feb; 55(4):1645-61. PubMed ID: 22257026
[TBL] [Abstract][Full Text] [Related]
18. PLS and shape-based similarity analysis of maleimides--GSK-3 inhibitors.
Crisan L; Pacureanu L; Avram S; Bora A; Avram S; Kurunczi L
J Enzyme Inhib Med Chem; 2014 Aug; 29(4):599-610. PubMed ID: 24047148
[TBL] [Abstract][Full Text] [Related]
19. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
[TBL] [Abstract][Full Text] [Related]
20. Thiazolo[5,4-f]quinazolin-9-ones, inhibitors of glycogen synthase kinase-3.
Testard A; Logé C; Léger B; Robert JM; Lozach O; Blairvacq M; Meijer L; Thiéry V; Besson T
Bioorg Med Chem Lett; 2006 Jul; 16(13):3419-23. PubMed ID: 16644220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
